MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
MEI Pharma, Inc. (MEIP)
Last mei pharma, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.meipharma.com
Company Research
Source: Business Wire
SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kd") inhibitor, in patients with relapsed or refractory (R/R) B-cell malignancy in The Lancet Oncology. The published data demonstrate that an intermittent dosing regimen of zandelisib resulted in lower cumulative risk of Grade 3 or worse adverse events of special interest compared to a continuous daily dosing regimen without loss of efficacy. The publication, entitled "Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory
Show less
Read more
Impact Snapshot
Event Time:
MEIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MEIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MEIP alerts
High impacting MEI Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
MEIP
News
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $7.00 price target on the stock.MarketBeat
MEIP
Earnings
- 2/13/24 - Miss
MEIP
Sec Filings
- 2/29/24 - Form EFFECT
- 2/28/24 - Form 424B5
- 2/21/24 - Form 8-K
- MEIP's page on the SEC website